Table 1.

Effect of MQ–IPTp vs. SP–IPTp on poor mother and child outcomes, univariate analysis, Benin, 2005–2008^*

Outcome	Missing data (n)	Prevalence in MQ group (%)	Prevalence in SP group (%)	Univariate comparison P value
LBW†	136	8.0	9.8	0.22
LBW‡	83	9.7	11.1	0.36
Placental malaria	282	1.7	4.4	0.004
Anemia	335	16.5	20.2	0.09
Low tolerability§	7	7.1	3.7	0.002

LBW = low birth weight; IPTp = intermittent preventive treatment; MQ = mefloquine; SP = sulfadoxine–pyrimethamine.

^*Missing data were excluded from the analyses; birth weights recorded in the event of stillbirth, spontaneous abortion, or multiple pregnancy were considered as missing data.

^†Results when not including birth weight of stillbirths, abortions, or multiple pregnancies.

^‡Results when including birth weight of stillbirths, abortions, or multiple pregnancies.

^§Low tolerability was defined as severe adverse event (SAE), reluctance—eventually followed by acceptance—to receive the second IPTp dose because of an adverse event (AE) at the first dose, or refusal to receive the second dose whatever the reason.